Korean biotech company GI Innovation said Monday it has received Fast Track Designation from the US Food and Drug Administration for GI-102, its next-generation ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in ...
Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal ...
Dr. Rubin highlights a new subcutaneous induction for UC, stressing convenience, access, and sustained remission.
The decision to clear another mifepristone generic sparked political backlash. Elsewhere, Medicare delayed a decision on whether to subject “combination” drugs to pricing negotiations, and a cancer ...
Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with multiple myeloma. While the use of subcutaneous daratumumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback